Advertisement

The molecular landscape of colitis-associated carcinogenesis

Published:December 22, 2016DOI:https://doi.org/10.1016/j.dld.2016.12.011

      Abstract

      In spite of the well-established histopathological phenotyping of IBD-associated preneoplastic and neoplastic lesions, their molecular landscape remains to be fully elucidated. Several studies have pinpointed the initiating role of longstanding/relapsing inflammatory insult on the intestinal mucosa, with the activation of different pro-inflammatory cytokines (TNF-α, IL-6, IL-10, IFN-γ), chemokines and metabolites of arachidonic acid resulting in the activation of key transcription factors such as NF-κB. Longstanding inflammation may also modify the intestinal microbiota, prompting the overgrowth of genotoxic microorganisms, which may act as further cancer promoters. Most of the molecular dysregulation occurring in sporadic colorectal carcinogenesis is documented in colitis-associated adenocarcinoma too, but marked differences have been established in both their timing and prevalence. Unlike sporadic cancers, TP53 alterations occur early in IBD-related carcinogenesis, while APC dysregulation emerges mainly in the most advanced stages of the oncogenic cascade. From the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of KRAS mutations than the sporadic variant. Epigenetic changes, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs, are significantly involved in colitis-associated cancer development and progression. The focus now is on identifying diagnostic and prognostic biomarkers, with a view to ultimately designing patient-tailored therapies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fassan M.
        • Baffa R.
        • Kiss A.
        Advanced precancerous lesions within the GI tract: the molecular background.
        Best Practice & Research Clinical Gastroenterology. 2013; 27: 159-169
        • Mescoli C.
        • Albertoni L.
        • D'inca R.
        • et al.
        Dysplasia in inflammatory bowel diseases.
        Digestive and Liver Disease. 2013; 45: 186-194
        • Eaden J.A.
        • Abrams K.R.
        • Mayberry J.F.
        The risk of colorectal cancer in ulcerative colitis: a meta-analysis.
        Gut. 2001; 48: 526-535
        • Gillen C.D.
        • Walmsley R.S.
        • Prior P.
        • et al.
        Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis.
        Gut. 1994; 35: 1590-1592
        • Bernstein C.N.
        • Blanchard J.F.
        • Kliewer E.
        • et al.
        Cancer risk in patients with inflammatory bowel disease: a population-based study.
        Cancer. 2001; 91: 854-862
        • Tsaitas C.
        • Semertzidou A.
        • Sinakos E.
        Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.
        World Journal of Hepatology. 2014; 6: 178-187
        • Askling J.
        • Dickman P.W.
        • Karlen P.
        • et al.
        Family history as a risk factor for colorectal cancer in inflammatory bowel disease.
        Gastroenterology. 2001; 120: 1356-1362
        • Nuako K.W.
        • Ahlquist D.A.
        • Mahoney D.W.
        • et al.
        Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study.
        Gastroenterology. 1998; 115: 1079-1083
        • Jess T.
        • Rungoe C.
        • Peyrin-Biroulet L.
        Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies.
        Clinical Gastroenterology and Hepatology. 2012; 10: 639-645
        • Ekbom A.
        • Helmick C.
        • Zack M.
        • et al.
        Ulcerative colitis and colorectal cancer. A population-based study.
        The New England Journal of Medicine. 1990; 323: 1228-1233
        • Soderlund S.
        • Brandt L.
        • Lapidus A.
        • et al.
        Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease.
        Gastroenterology. 2009; 136 ([quiz 1818–9]): 1561-1567
        • Brackmann S.
        • Andersen S.N.
        • Aamodt G.
        • et al.
        Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
        Scandinavian Journal of Gastroenterology. 2009; 44: 46-55
        • Jess T.
        • Simonsen J.
        • Jorgensen K.T.
        • et al.
        Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.
        Gastroenterology. 2012; 143 (e1; [quiz e13–4]): 375-381
        • Farraye F.A.
        • Odze R.D.
        • Eaden J.
        • et al.
        AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.
        Gastroenterology. 2010; 138: 738-745
        • Cairns S.R.
        • Scholefield J.H.
        • Steele R.J.
        • et al.
        Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002).
        Gut. 2010; 59: 666-689
        • Collins P.D.
        • Mpofu C.
        • Watson A.J.
        • et al.
        Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.
        Cochrane Database of Systematic Reviews. 2006; 2: CD000279
        • Rutter M.D.
        • Saunders B.P.
        • Wilkinson K.H.
        • et al.
        Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.
        Gastroenterology. 2006; 130: 1030-1038
        • Zisman T.L.
        • Rubin D.T.
        Colorectal cancer and dysplasia in inflammatory bowel disease.
        World Journal of Gastroenterology. 2008; 14: 2662-2669
        • Manuc T.E.
        • Manuc M.M.
        • Diculescu M.M.
        Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets.
        Clinical and Experimental Gastroenterology. 2016; 9: 59-70
        • Boyapati R.K.
        • Kalla R.
        • Satsangi J.
        • et al.
        Biomarkers in search of precision medicine in IBD.
        The American Journal of Gastroenterology. 2016; 111: 1682-1690
        • Xie J.
        • Itzkowitz S.H.
        Cancer in inflammatory bowel disease.
        World Journal of Gastroenterology. 2008; 14: 378-389
        • Ullman T.
        • Odze R.
        • Farraye F.A.
        Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon.
        Inflammatory Bowel Diseases. 2009; 15: 630-638
        • Cornaggia M.
        • Leutner M.
        • Mescoli C.
        • et al.
        Chronic idiopathic inflammatory bowel diseases: the histology report.
        Digestive and Liver Disease. 2011; 43: S293-303
        • Eaden J.
        • Abrams K.
        • McKay H.
        • et al.
        Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis.
        The Journal of Pathology. 2001; 194: 152-157
        • Langner C.
        • Magro F.
        • Driessen A.
        • et al.
        The histopathological approach to inflammatory bowel disease: a practice guide.
        Virchows Archiv. 2014; 464: 511-527
        • Allende D.
        • Elmessiry M.
        • Hao W.
        • et al.
        Inter-observer and intra-observer variability in the diagnosis of dysplasia in patients with inflammatory bowel disease: correlation of pathological and endoscopic findings.
        Colorectal Disease. 2014; 16 ([discussion 718]): 710-718
        • Magro F.
        • Langner C.
        • Driessen A.
        • et al.
        European consensus on the histopathology of inflammatory bowel disease.
        Journal of Crohn’s and Colitis. 2013; 7: 827-851
        • Riddell R.H.
        • Goldman H.
        • Ransohoff D.F.
        • et al.
        Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.
        Human Pathology. 1983; 14: 931-968
        • Harpaz N.
        • Ward S.C.
        • Mescoli C.
        • et al.
        Precancerous lesions in inflammatory bowel disease.
        Best Practice & Research Clinical Gastroenterology. 2013; 27: 257-267
        • Bressenot A.
        • Cahn V.
        • Danese S.
        • et al.
        Microscopic features of colorectal neoplasia in inflammatory bowel diseases.
        World Journal of Gastroenterology. 2014; 20: 3164-3172
        • Engelsgjerd M.
        • Farraye F.A.
        • Odze R.D.
        Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.
        Gastroenterology. 1999; 117 ([discussion 1488–91]): 1288-1294
        • Kiran R.P.
        • Ahmed Ali U.
        • Nisar P.J.
        • et al.
        Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy.
        Annals of Surgery. 2014; 259: 302-309
        • Delaunoit T.
        • Limburg P.J.
        • Goldberg R.M.
        • et al.
        Colorectal cancer prognosis among patients with inflammatory bowel disease.
        Clinical Gastroenterology and Hepatology. 2006; 4: 335-342
        • Ullman T.A.
        • Itzkowitz S.H.
        Intestinal inflammation and cancer.
        Gastroenterology. 2011; 140: 1807-1816
        • Itzkowitz S.H.
        • Yio X.
        Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation.
        American Journal of Physiology—Gastrointestinal and Liver Physiology. 2004; 287: G7-17
        • Matula S.
        • Croog V.
        • Itzkowitz S.
        • et al.
        Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.
        Clinical Gastroenterology and Hepatology. 2005; 3: 1015-1021
        • Eaden J.
        Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease.
        Alimentary Pharmacology & Therapeutics. 2003; 18: 15-21
        • Nieminen U.
        • Jussila A.
        • Nordling S.
        • et al.
        Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.
        International Journal of Cancer. 2014; 134: 189-196
        • Yang G.Y.
        • Taboada S.
        • Liao J.
        Inflammatory bowel disease: a model of chronic inflammation-induced cancer.
        Methods in Molecular Biology. 2009; 511: 193-233
        • Becker C.
        • Fantini M.C.
        • Wirtz S.
        • et al.
        IL-6 signaling promotes tumor growth in colorectal cancer.
        Cell Cycle. 2005; 4: 217-220
        • Becker C.
        • Fantini M.C.
        • Schramm C.
        • et al.
        TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.
        Immunity. 2004; 21: 491-501
        • Grivennikov S.
        • Karin E.
        • Terzic J.
        • et al.
        IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.
        Cancer Cell. 2009; 15: 103-113
        • Mitsuyama K.
        • Matsumoto S.
        • Rose-John S.
        • et al.
        STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice.
        Gut. 2006; 55: 1263-1269
        • Li Y.
        • de Haar C.
        • Chen M.
        • et al.
        Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
        Gut. 2010; 59: 227-235
        • Matsumoto S.
        • Hara T.
        • Mitsuyama K.
        • et al.
        Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
        The Journal of Immunology. 2010; 184: 1543-1551
        • Agoff S.N.
        • Brentnall T.A.
        • Crispin D.A.
        • et al.
        The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
        American Journal of Pathology. 2000; 157: 737-745
        • Federico A.
        • Morgillo F.
        • Tuccillo C.
        • et al.
        Chronic inflammation and oxidative stress in human carcinogenesis.
        International Journal of Cancer. 2007; 121: 2381-2386
        • Meira L.B.
        • Bugni J.M.
        • Green S.L.
        • et al.
        DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice.
        The Journal of Clinical Investigation. 2008; 118: 2516-2525
        • Mangerich A.
        • Knutson C.G.
        • Parry N.M.
        • et al.
        Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer.
        Proceedings of the National Academy of Sciences of the United States of America. 2012; 109: E1820-E1829
        • Kado S.
        • Uchida K.
        • Funabashi H.
        • et al.
        Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice.
        Cancer Research. 2001; 61: 2395-2398
        • Ivanov I.I.
        • Atarashi K.
        • Manel N.
        • et al.
        Induction of intestinal Th17 cells by segmented filamentous bacteria.
        Cell. 2009; 139: 485-498
        • Mazmanian S.K.
        • Round J.L.
        • Kasper D.L.
        A microbial symbiosis factor prevents intestinal inflammatory disease.
        Nature. 2008; 453: 620-625
        • Round J.L.
        • Mazmanian S.K.
        The gut microbiota shapes intestinal immune responses during health and disease.
        Nature Reviews Immunology. 2009; 9: 313-323
        • Schottelius A.J.
        • Mayo M.W.
        • Sartor R.B.
        • et al.
        Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding.
        The Journal of Biological Chemistry. 1999; 274: 31868-31874
        • Berg D.J.
        • Davidson N.
        • Kuhn R.
        • et al.
        Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.
        The Journal of Clinical Investigation. 1996; 98: 1010-1020
        • Suzuki H.
        • Harpaz N.
        • Tarmin L.
        • et al.
        Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers.
        Cancer Research. 1994; 54: 4841-4844
        • O'Sullivan J.N.
        • Bronner M.P.
        • Brentnall T.A.
        • et al.
        Chromosomal instability in ulcerative colitis is related to telomere shortening.
        Nature Genetics. 2002; 32: 280-284
        • Risques R.A.
        • Lai L.A.
        • Brentnall T.A.
        • et al.
        Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage.
        Gastroenterology. 2008; 135: 410-418
        • Burmer G.C.
        • Rabinovitch P.S.
        • Haggitt R.C.
        • et al.
        Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele.
        Gastroenterology. 1992; 103: 1602-1610
        • Chaubert P.
        • Benhattar J.
        • Saraga E.
        • et al.
        K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis.
        American Journal of Pathology. 1994; 144: 767-775
        • Holzmann K.
        • Klump B.
        • Borchard F.
        • et al.
        Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis.
        International Journal of Cancer. 1998; 76: 1-6
        • Yin J.
        • Harpaz N.
        • Tong Y.
        • et al.
        P53 point mutations in dysplastic and cancerous ulcerative colitis lesions.
        Gastroenterology. 1993; 104: 1633-1639
        • Greenwald B.D.
        • Harpaz N.
        • Yin J.
        • et al.
        Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis.
        Cancer Research. 1992; 52: 741-745
        • Harpaz N.
        • Peck A.L.
        • Yin J.
        • et al.
        P53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma.
        Human Pathology. 1994; 25: 1069-1074
        • Parenti A.R.
        • Rugge M.
        • Frizzera E.
        • et al.
        P53 overexpression in the multistep process of esophageal carcinogenesis.
        The American Journal of Surgical Pathology. 1995; 19: 1418-1422
        • Hussain S.P.
        • Amstad P.
        • Raja K.
        • et al.
        Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease.
        Cancer Research. 2000; 60: 3333-3337
        • Cooks T.
        • Pateras I.S.
        • Tarcic O.
        • et al.
        Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.
        Cancer Cell. 2013; 23: 634-646
        • Tarmin L.
        • Yin J.
        • Harpaz N.
        • et al.
        Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms.
        Cancer Research. 1995; 55: 2035-2038
        • Fogt F.
        • Vortmeyer A.O.
        • Goldman H.
        • et al.
        Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma.
        Human Pathology. 1998; 29: 131-136
        • Umetani N.
        • Sasaki S.
        • Watanabe T.
        • et al.
        Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability.
        Japanese Journal of Cancer Research. 1999; 90: 1081-1087
        • Redston M.S.
        • Papadopoulos N.
        • Caldas C.
        • et al.
        Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias.
        Gastroenterology. 1995; 108: 383-392
        • Burmer G.C.
        • Levine D.S.
        • Kulander B.G.
        • et al.
        c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma.
        Gastroenterology. 1990; 99: 416-420
        • Bell S.M.
        • Kelly S.A.
        • Hoyle J.A.
        • et al.
        c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis.
        British Journal of Cancer. 1991; 64: 174-178
        • Robles A.I.
        • Traverso G.
        • Zhang M.
        • et al.
        Whole-exome Sequencing analyses of inflammatory bowel disease-associated colorectal cancers.
        Gastroenterology. 2016; 150: 931-943
        • Hsieh C.J.
        • Klump B.
        • Holzmann K.
        • et al.
        Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis.
        Cancer Research. 1998; 58: 3942-3945
        • Matsumura S.
        • Oue N.
        • Ito R.
        • et al.
        The promoter methylation status of the DNA repair gene O6-methylguanine-DNA methyltransferase in ulcerative colitis.
        Virchows Archiv. 2003; 443: 518-523
        • Fujiwara I.
        • Yashiro M.
        • Kubo N.
        • et al.
        Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway.
        Diseases of the Colon & Rectum. 2008; 51: 1387-1394
        • Fleisher A.S.
        • Esteller M.
        • Harpaz N.
        • et al.
        Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1.
        Cancer Research. 2000; 60: 4864-4868
        • Katsurano M.
        • Niwa T.
        • Yasui Y.
        • et al.
        Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction.
        Oncogene. 2012; 31: 342-351
        • Konishi K.
        • Shen L.
        • Wang S.
        • et al.
        Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias.
        Gastroenterology. 2007; 132: 1254-1260
        • Sanchez J.A.
        • Dejulius K.L.
        • Bronner M.
        • et al.
        Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
        Inflammatory Bowel Diseases. 2011; 17: 1966-1970
        • Fassan M.
        • Croce C.M.
        • Rugge M.
        miRNAs in precancerous lesions of the gastrointestinal tract.
        World Journal of Gastroenterology. 2011; 17: 5231-5239
        • D'Angelo E.
        • Vicentini C.
        • Agostini M.
        • et al.
        MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis.
        Current Drug Targets. 2015; 16: 383-392
        • Fassan M.
        • Baffa R.
        MicroRNAs and targeted therapy: small molecules of unlimited potentials.
        Current Opinion in Genetics & Development. 2013; 23: 75-77
        • Wu F.
        • Zikusoka M.
        • Trindade A.
        • et al.
        MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha.
        Gastroenterology. 2008; 135 (e24): 1624-1625
        • Valeri N.
        • Braconi C.
        • Gasparini P.
        • et al.
        MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.
        Cancer Cell. 2014; 25: 469-483
        • Ludwig K.
        • Fassan M.
        • Mescoli C.
        • et al.
        PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis.
        Virchows Archiv. 2013; 462: 57-63
        • Paraskevi A.
        • Theodoropoulos G.
        • Papaconstantinou I.
        • et al.
        Circulating MicroRNA in inflammatory bowel disease.
        Journal of Crohn’s and Colitis. 2012; 6: 900-904
        • Fisher K.
        • Lin J.
        MicroRNA in inflammatory bowel disease: translational research and clinical implication.
        World Journal of Gastroenterology. 2015; 21: 12274-12282